# **Deep Learning of Left Atrial Structure and Function**

# **Provides Link to Atrial Fibrillation Risk**

James P. Pirruccello<sup>1,2,3,4</sup>, Paolo Di Achille<sup>3,5</sup>, Seung Hoan Choi<sup>6</sup>, Shaan Khurshid<sup>1,2,3,4</sup>, Mahan Nekoui<sup>3,4</sup>, Sean J. Jurgens<sup>3,7</sup>, Victor Nauffal<sup>3,8</sup>, Kenney Ng<sup>9</sup>, Samuel F. Friedman<sup>3,5</sup>, Kathryn L. Lunetta<sup>10</sup>, Anthony A. Philippakis<sup>5</sup>, Jennifer E. Ho<sup>1,2,4</sup>, Steven A. Lubitz<sup>1,2,3,4</sup>, Patrick T. Ellinor<sup>1,2,3,4</sup>

- 1 Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA
- 2 Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
- 3 Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- 4 Harvard Medical School, Boston, Massachusetts, USA
- 5 Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- 6 Cardiovascular Disease Initiative, Broad Institute, Cambridge, Massachusetts, USA
- 7 Department of Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, NL
- 8 Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
- 9 IBM Research, Cambridge, Massachusetts, USA
- 10 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA

Running Title: Deep learning of left atrial traits

#### **Corresponding Author:**

James P. Pirruccello, MD Cardiology Division Massachusetts General Hospital 185 Cambridge Street, CPZN / 3.187 Boston, MA 02114 jamesp@broadinstitute.org

## Abstract

2 Aims

1

7

- 3 Increased left atrial (LA) volume is a known risk factor for atrial fibrillation (AF). There is also emerging
- 4 evidence that alterations in LA function due to an atrial cardiomyopathy are associated with an increased
- 5 risk of AF. The availability of large-scale cardiac MRI data paired with genetic data provides a unique
- 6 opportunity to assess the joint genetic contributions of LA structure and function to AF risk.

#### Methods and results

- 8 We developed deep learning models to measure LA traits from cardiovascular magnetic resonance
- 9 imaging (MRI) in 40,558 UK Biobank participants and integrated these data to estimate LA minimum
- 10 (LAmin), maximum (LAmax), and stroke volume (LASV), as well as emptying fraction (LAEF). We
- 11 conducted a genome-wide association study (GWAS) in 35,049 participants without pre-existing
- 12 cardiovascular disease, identifying 20 common genetic loci associated with LA traits. Eight of the loci
- 13 associated with LA traits were previously associated with AF: the AF risk alleles were associated with an
- 14 increased LA minimum volume (LAmin) and a decreased LAEF. A Mendelian randomization analysis
- 15 confirmed that AF causally affects LA volume (IVW P = 6.2E-06), and provided evidence that LAmin
- 16 causally affects AF risk (IVW P = 4.7E-05). In UK Biobank participants, a polygenic prediction of
- 17 LAmin was significantly associated with risk for AF (HR 1.09 per SD; P = 1.6E-36) and ischemic stroke
- 18 (HR 1.04 per SD; P = 4.7E-03).

#### **Conclusions**

- We performed the largest and highest resolution assessment of LA structure and function to date. We then
- 21 identified 20 common genetic variants associated with LA volumes or LAEF, 19 of which were novel.
- We found that a polygenic prediction of the minimal LA volume was associated with AF and stroke.
- Finally, we found an inverse relation between genetic variants associated with AF risk and LAEF. Our
- 24 findings provide evidence of a causal relation between LA contractile function and AF.

1 **Keywords**: Left atrium, machine learning, cardiovascular disease, genetics, atrial fibrillation

Introduction Atrial fibrillation (AF) is a common arrhythmia that is projected to affect up to 12 million Americans by 2050<sup>1</sup>. As a leading cause of stroke<sup>2,3</sup>, the risk factors for AF have been the subject of extensive investigation<sup>4-6</sup>. Enlargement of left atrial (LA) volumes is commonly observed with hypertension<sup>7</sup>, heart failure<sup>8</sup>, or after a diagnosis of AF<sup>9,10</sup>—and AF plays a causal role in this process<sup>11</sup>. Enlargement of the LA and decreased LA function have also been identified as independent risk factors for AF<sup>10,12-17</sup> and stroke<sup>18-20</sup>. Together these atrial structural, contractile, or electrophysiological changes that have clinical consequences have been termed atrial cardiomyopathies<sup>21,22</sup>. The link between LA function and AF risk has prompted interest in determining the heritability and common genetic basis for variation in LA measurements. A large-scale genome-wide association study (GWAS) in 30,201 individuals with LA measurements ascertained by echocardiography did not identify any loci with P < 5E-08<sup>23</sup>. Recently, a genome-wide association study of deep learning-derived diastolic measurements in 34,245 UK Biobank participants identified one variant associated with LA volume near  $NPR3^{24,25}$ . 16 Taking advantage of the precision of cardiovascular magnetic resonance imaging (MRI), we developed deep learning models to produce two-dimensional measurements of the LA in 40,558 participants in the UK Biobank<sup>26,27</sup>, and applied a surface reconstruction technique to integrate these data into threedimensional LA volume estimates. We reproduced prior observational associations between LA measurements and AF, heart failure, hypertension, and stroke. We then undertook analyses to identify common genetic variants associated with LA volumes in over 35,000 UK Biobank participants. Finally, using common genetic variants as instruments for Mendelian randomization, we performed bidirectional causal analyses between LA volume and AF.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

17

18

19

20

21

22

23

Results

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Reconstruction of LA volumes from cardiovascular magnetic resonance images We trained deep learning models to annotate the LA and left ventricular blood pools in four views (distinct models for the short axis view, and the two-, three-, and four-chamber long axis views). We then applied these models to all available UK Biobank cardiovascular magnetic resonance imaging (MRI) data (Online Methods)<sup>26–28</sup>. The quality of the deep learning models for measuring the LA was high for the long axis views, and as expected, lower for the short axis views because this view was not designed to capture the LA (Supplementary Note). We integrated the data from these separate cross-sections to compute the surface of a 3-dimensional representation of the LA, yielding LA volume estimates at 50 timepoints throughout the cardiac cycle for 40,558 participants (Figure 1). We conducted analyses on the maximum LA volume (LAmax), the minimum LA volume (LAmin), the difference between those two volumes (stroke volume; LASV), and the emptying fraction (LASV/LAmax; LAEF). LA traits are associated with AF, heart failure and stroke We analyzed the pattern of cardiac chamber volumes throughout the cardiac cycle in order to identify individuals with abnormal atrial contraction (Supplementary Note). Interestingly, a subset of 1,013 participants with abnormal atrial contraction had markedly elevated LA volumes, similar to those with pre-existing AF (**Figure 2**), and were excluded from downstream analyses. In the remaining 39,545 participants, we evaluated the association between LA measurements and prevalent or incident AF (Supplementary Note). The LA phenotype most strongly associated with AF was the LA minimal volume (LAmin). The 813 individuals with pre-existing AF had a greater LAmin (+8.8 mL, P = 9.2 E-117). In the ~2.2 years of follow-up time available on average after MRI acquisition, the risk of incident AF was increased among those with greater LAmin (293 cases; HR 1.73 per standard deviation [SD] increase; 95% CI 1.60-1.88; P = 4.0E-39). We also observed significant associations

1 between LA measurements and hypertension, heart failure, and stroke (Figure 3 and Supplementary 2 **Tables 1-3**). Common genetic variant analysis of LA size and function identifies 20 loci 3 4 After establishing that the LA measurements replicated previously established clinical associations, we 5 then examined the association between common genetic variants and seven LA traits. We conducted these 6 analyses in 35,049 participants with genetic data and without a history of AF, coronary artery disease, or 7 heart failure (Table 1; Supplementary Figure 1). First, we examined the SNP-heritability of the LA 8 traits which ranged from 0.17 (LAEF) to 0.37 (LAmax; Supplementary Table 4). Genetic correlation 9 between the LA measurements ranged from 0.23 (between LAmax and LAEF) to 0.85 (between LAmax 10 and LAmin; Supplementary Table 4). 11 12 Next, we performed genome-wide association studies (GWAS) for LAmax, LAmin, LAEF, and LASV, 13 as well as for body surface area (BSA)-indexed LA volumes (Table 2). Finally, as a sensitivity analysis, 14 we performed GWAS of LA volumes after indexing on left ventricular end diastolic volume 15 (Supplementary Materials and Supplementary Figure 2). For all analyses, linkage disequilibrium 16 score regression intercepts were near 1, indicating no significant evidence of inflation due to population 17 stratification (**Supplementary Table 5**)<sup>29</sup>. 18 19 In the GWAS of LA traits conducted without indexing to BSA, we identified five loci associated with 20 LAmax, eight with LAmin, four with LAEF, and two with LASV (Figure 4). Four loci were shared 21 between LAmax and LAmin, with lead SNPs near HLA-B, IRAK1BP1, BEND3, and FBXO32/RSPH6A. 22 LAmax was additionally associated with SNPs at the HMGA2 locus, and LAmin was associated with 23 SNPs near ANKRD1, SSSCA1, IGF1R, and MYO18B. The four LAEF loci were located near FAF1, 24 CASQ2, MYH6, and MYO18B. The two LASV-associated loci included SNPs near HLA-C and MYH6. 25

1 Indexing on BSA yielded three additional loci shared by both LAmax and LAmin (TTN, PITX2, and 2 NPR3), as well as MY018B for LAmax, UOCRB, HTR7, and GOSR2 for LAmin, and OBP2B for LASV. 3 Additional loci were identified in a sensitivity analysis that accounted for left ventricular end diastolic 4 volume (LVEDV; Supplementary Table 6). Because adjustment for heritable covariates can induce spurious association signals, interpretation of these loci requires caution (see **Supplementary Note**)<sup>30</sup>. 5 Genetic relationship between AF risk and LA dysfunction 6 7 To gain more insight into the genetic relationship between LA measurements and AF, we first evaluated 8 their genetic correlations. Using *ldsc*, the strongest genetic correlation was found between LAmin and AF 9 (rg 0.37, P = 2.0E-10), a direction of effect that corresponds to a positive correlation between LA dysfunction (i.e., increased LAmin) and risk for AF (**Supplementary Table 7**)<sup>31,32</sup>. We also tested for 10 11 association between LA measurements and stroke (all-cause or cardioembolic) from MEGASTROKE; the 12 strongest association was between LAmin and all-cause stroke with nominal significance (rg 0.21, P = 0.01), which was directionally concordant with increased AF risk<sup>33</sup>. 13 14 15 We then assessed the overlap between the 20 distinct LA loci identified in our study and 134 loci previously found to be associated with AF<sup>32</sup>. We found that 8 of the 20 LA loci overlapped with an AF 16 17 locus, which was a significant enrichment based on permutation testing (P = 2E-04; minimum possible P= 1E-04, see Methods)<sup>34</sup>. The 8 loci found in both the LA GWAS and the AF GWAS are nearest to 18 FAF1/C1orf85, CASO2, TTN, PITX2, MYH6/MYH7, IGF1R, GOSR2, and MYO18B. At all 8 loci, the 19 20 effect of each SNP on AF risk was in opposition to its effect on LAEF, and in most cases the effect of 21 each SNP on AF was concordant with its effect on LAmin (Figure 5). None of the loci that were linked 22 with both LA measurements and AF were associated at genome-wide significance with LAmax. Causal link between LA minimal volume and AF risk 23 24 Because the genetic correlation analysis suggested that the strongest cross-trait association was between 25 LAmin and AF, we performed bidirectional Mendelian randomization (MR) analyses to assess whether

LA Genetics - Page 6 of 44

this relationship was causal. First, we assessed the causal effects of LAmin on the risk for AF. Variants that were associated with LAmin with P < 1E-06 were clumped and ambiguous alleles were excluded, leaving 19 SNPs. These variants were looked up in summary statistics from a prior AF GWAS without UK Biobank participants to model the outcome<sup>35</sup>. The inverse variance weighted (IVW) model identified a significant association between LAmin and AF (OR 1.77 per SD increase in LAmin, 95% CI 1.3-2.3, P = 4.7E-05). Simple median, weighted median, MR Egger, and MR-PRESSO showed the same direction of effects (Supplementary Figure 3). MR-Egger results did not reach nominal significance, and did not yield evidence for horizontal pleiotropy (intercept P = 0.48). Within the subset of the UK Biobank with imaging data available, three of the 19 SNPs had evidence for pleiotropic association with AF risk factors (Supplementary Figure 4) that we derived from the CHARGE-AF risk score<sup>4</sup>. A sensitivity analysis excluding these three variants yielded similar results (IVW OR 1.89 per SD increase in LAmin, P = 7.3E-12 06; Supplementary Table 8; Supplementary Figure 5). 13 14 We also tested the causal effect of AF on LAmin, with 36 instruments taken from the 2017 AF GWAS, conducted without UK Biobank participants, that were also available in the LAmin summary statistics<sup>35</sup>. 16 Increasing genetic risk of AF was significantly associated with LAmin (0.086 mL increase per unit increase of log of odds of AF liability, 95% CI 0.049-0.123 mL, P = 6.2E-06) using the IVW approach. The simple median, weighted median, MR-Egger, and MR-PRESSO exhibited similar directional effects and a nominal significance. The intercept of the MR-Egger and MR-Egger bootstrap were not significantly different from zero (MR-Egger intercept P = 0.83, MR-Egger bootstrap intercept P = 0.40; **Supplementary Figure 6).** A polygenic risk score for AF is associated with LA phenotypes 23 We constructed a 1.1-million SNP polygenic risk score (PRS) with PRScs from the Christophersen, et al, AF GWAS that did not include UK Biobank participants, and applied this score in UK Biobank participants with imaging <sup>35,36</sup>. After excluding participants with a history of AF diagnosed prior to MRI,

1

2

3

4

5

6

7

8

9

10

11

15

17

18

19

20

21

22

24

- 1 and participants with abnormal atrial contraction, 36,518 participants remained for analysis. The AF PRS
- 2 was statistically significantly associated with all measures of LA size and function, with a small effect
- 3 size (Supplementary Table 9). The strongest association was with LAmin (0.049 SD increase in LAmin
- 4 per SD increase in the PRS; 95% CI 0.039-0.058; P = 9.8E-24).
- 5 A polygenic estimate of LA volume predicts AF, stroke, and heart failure
- 6 We created a 1.1 million SNP genome-wide polygenic score for each LA trait using PRScs<sup>36</sup>. We tested
- 7 this score in the 421,339 UK Biobank participants who did not participate in the LA GWAS, of whom
- 8 22,356 developed AF. The strongest association was with the BSA-indexed LAmin polygenic score,
- 9 which was linked to a modestly increased risk for incident AF or atrial flutter (HR = 1.09 per 1 SD
- increase in the score; P = 1.6E-36) (**Figure 6**; **Supplementary Table 10**). This score was also associated
- 11 with small increases in risks of incident all-cause stroke (7,823 cases; HR = 1.04 per SD; P = 4.7E-04),
- ischemic stroke (5,492 cases; HR = 1.04 per SD; P = 4.7E-03), and heart failure (11,465 cases; HR = 1.05
- per SD; P = 2.6E-08). In a sensitivity analysis that censored participants who developed AF prior to a
- 14 diagnosis of heart failure, the magnitude of effect and strength of association between the LAmin score
- and heart failure was attenuated (8,247 cases; HR = 1.03 per SD; P = 0.01; **Supplementary Table 11**).

#### 16 Discussion

- We used a unique resource of more than 40,000 cardiac MRI images available in the UK Biobank to
- 18 enable one of the largest and highest resolution assessments of LA structure and function to date. We
- trained deep learning models to segment LA cross sections from cardiovascular MRI data and then
- derived estimates of LA volume. In turn, we performed an extensive series of epidemiological, genetic,
- 21 polygenic and Mendelian randomization analyses to link these LA traits to cardiovascular outcomes. Our
- 22 findings permit at least five primary conclusions.

First, we were able to replicate previous observations demonstrating associations between greater LA volume and cardiovascular diseases <sup>7–10,19,20</sup>. Participants with a history of AF had larger LA volumes; and participants with larger LA volumes were more likely to be subsequently diagnosed with AF, stroke, or heart failure. Second, these measurements enabled the largest genetic analysis to date of LA measurements. To our knowledge, one locus (near NPR3) has previously been associated at genome-wide significance with LA measurements<sup>25</sup>. In this work, 20 distinct genetic loci were associated with LAmax, LAmin, LAEF, LASV, or the BSA-indexed versions of these phenotypes. Forty percent of these loci (8 of 20) were previously associated with AF, significantly more than expected by chance.<sup>32</sup>. At all 8 loci, the allele associated with increased AF risk was directionally associated with a lower LAEF, and generally with greater LA volumes. The uniformly opposed effect directions of these SNPs for AF risk and LAEF may be consistent with the concept of atrial cardiomyopathy<sup>22</sup>. As an example of the pattern of opposed SNP effects on LAEF and AF risk, we identified a missense variant within CASO2 (rs4074536; p.Thr66Ala) as a lead SNP for LAEF on chromosome 1. The T allele of this SNP (encoding Thr66) corresponds with a reduced LAEF in our GWAS, and with reduced expression of CASO2 in the right atrial appendage and left ventricle in GTEx<sup>37</sup>. This variant is also in LD  $(r^2=1.0)$  in non-African 1KG populations for the AF lead SNP rs4484922<sup>32,38</sup>. In the study by Roselli and colleagues, the rs4484922-G allele is associated with an increased risk for AF; notably, that riskincreasing allele corresponds to the LAEF-reducing T allele of rs4074536. The rs4074536-T allele has also previously been associated with a longer QRS complex duration <sup>39,40</sup>. CASQ2 encodes calsequestrin 2, which resides in the sarcoplasmic reticulum in abundance and binds to calcium ions during the cardiac cycle. Missense variants in this gene have also been associated with catecholamine-induced polymorphic ventricular tachycardia, typically following a recessive inheritance pattern<sup>41,42</sup>.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Even among LA-associated loci that were not previously associated with AF, several showed the same consistent pattern of inverse effect between AF risk and LAEF (e.g., near NPR3, SSSCA1, and HMGA2). However, this pattern did not uniformly hold. For example, at the gene-dense locus near FBXO46/DMWD/RPSH6A, the LA volume-increasing (and LAEF-decreasing) variants were weakly associated with decreased AF risk. Also notable was the PITX2 locus, which was the first locus associated with AF. In the present GWAS, SNPs at that locus were associated with BSA-indexed LAmax and LAmin. The lead SNP for AF (rs2129977 from Roselli, et al, 2018) was in close LD with the lead SNP for LAmax and LAmin  $(rs2634073; r^2 = 0.85)^{32,38}$ . Consistent with clinical expectations, the AF risk allele was associated with greater left atrial maximum and minimum volumes. These analyses excluded participants with a history of AF or abnormal atrial contraction on MRI; therefore, these results support the hypothesis that the PITX2 locus may be associated with an increase in LA volume that occurs prior to AF onset. Fourth, we developed polygenic scores to gain additional insight into the relationship between LA volumes and cardiovascular diseases. A genome-wide 1.1-million variant AF PRS derived from Christophersen, et al., 2017 was associated with all of the LA phenotypes—and most strongly with LAmin—even after excluding participants known to have AF<sup>35</sup>. This genetic evidence is consistent with and extends prior observational evidence, and suggests that some of the genetic drivers of AF risk may manifest in ways that are detectable in LA size and function. A 1.1-million variant polygenic predictor of BSA-indexed LAmin was modestly associated with incident AF (Figure 6), and weakly with stroke, in the UK Biobank. The score was also associated with heart failure—an association which was almost completely attenuated after excluding participants who were diagnosed with AF prior to heart failure. This attenuation suggests that much of the heart failure association may be mediated through AF.

LA Genetics - Page 10 of 44

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Finally, we found strong evidence of genetic correlation between LA phenotypes and AF. We pursued Mendelian randomization analyses to more formally assess the hypothesis of bidirectional causation between LA phenotypes and AF. These revealed strong evidence of a causal effect of AF on LAmin, as has been previously observed<sup>11</sup>. There was also evidence that LA volumes, particularly LAmin, may be causal for AF. The causal effect persisted even after excluding three variants associated with at least one risk factor from CHARGE-A<sup>4</sup>. However, because AF can be paroxysmal and remain undiagnosed, we cannot exclude the possibility of cryptic reverse causation: namely, that some participants may have had larger atria because of undiagnosed paroxysmal AF, such that AF itself induced the genetic association with LA volumes. Limitations This study has several limitations. All LA measurements were derived from deep learning models of cardiovascular MRI. Because a complete trans-axial stack of atrial images was not part of the UK Biobank imaging protocol, the LA measurements are estimates that are interpolated from cross sections of the LA. Because contrast protocols were not used during image acquisition, we were not able to ascertain atrial fibrosis. The deep learning models have not been tested outside of the specific devices and imaging protocols used by the UK Biobank and are unlikely to generalize to other data sets without fine tuning. Disease labels were determined by diagnostic and procedural codes; because AF can be paroxysmal and may go undetected, it is likely that a subset of the participants had undiagnosed AF prior to MRI, which would bias causal estimates of the impact of LA volume on disease risk away from the null. The study population was largely composed of people of European ancestries, limiting generalizability of the findings to global populations. The participants who underwent MRI in the UK Biobank tended to be healthier than the remainder of the UK Biobank population, which itself is likely to be healthier than the general population. At present, there is little follow-up time subsequent to the first MRI visit for most UK Biobank participants.

1

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

## Conclusions

1

7

- 2 Measures of LA structure and function are heritable traits that are associated with AF, stroke, and heart
- 3 failure. Genetic predictors of LA volume are linked to an elevated risk of AF and, to a lesser extent,
- 4 stroke and heart failure. In future work, it will be interesting to determine if targeting the genes and
- 5 pathways associated with abnormalities in LA function will be helpful to reduce the risk of AF, heart
- 6 failure, and stroke.

## Methods

1

2

8

11

## Study design

- 3 Except where otherwise stated, all analyses were conducted in the UK Biobank, which is a richly
- 4 phenotyped, prospective, population-based cohort that recruited 500,000 participants aged 40-69 years in
- 5 the UK via mailer from 2006-2010<sup>43</sup>. We analyzed 487,283 participants with genetic data who had not
- 6 withdrawn consent as of February 2020. Access was provided under application #7089 and approved by
- 7 the Partners HealthCare institutional review board (protocol 2019P003144).
- 9 Statistical analyses were conducted with R version 3.6 (R Foundation for Statistical Computing, Vienna,
- 10 Austria).

#### Cardiovascular magnetic resonance imaging protocols

- 12 At the time of this study, the UK Biobank had released images in over 45,000 participants of an imaging
- substudy that is ongoing<sup>26,27</sup>. Cardiovascular magnetic resonance imaging was performed with 1.5 Tesla
- scanners (Syngo MR D13 with MAGNETOM Aera scanners; Siemens Healthcare, Erlangen, Germany),
- and electrocardiographic gating for synchronization<sup>27</sup>. Several cardiac views were obtained. For this
- study, four views (the long axis two-, three-, and four-chamber views, as well as the short axis view) were
- 17 used. In these views, balanced steady-state free precession cines, consisting of a series of 50 images
- throughout the cardiac cycle for each view, were acquired for each participant<sup>27</sup>. For the three long axis
- views, only one imaging plane was available for each participant, with an imaging plane thickness of
- 20 6mm and an average pixel width and height of 1.83mm. For the short axis view, several imaging planes
- 21 were acquired. Starting at the base of the heart, 8mm-thick imaging planes were acquired with
- 22 approximately 2mm gaps between each plane, forming a stack perpendicular to the longitudinal axis of
- 23 the left ventricle to capture the ventricular volume. For the short axis images, the average pixel width and
- height was 1.86mm.

Semantic segmentation and quality control We labeled pixels using a process similar to that described in our prior work evaluating the thoracic aorta<sup>44</sup>. Cardiac structures were manually annotated in images from the short axis view and the two-, three-, and four-chamber long axis views from the UK Biobank by a cardiologist (JPP). To produce the models used in this manuscript, 714 short axis images were chosen, manually segmented, and used to train a deep learning model with PyTorch and fastai v1.0.61<sup>28,45</sup>. The same was done separately with 98 two-chamber images, 66 three-chamber images, and 445 four-chamber images. The models were based on a U-Net-derived architecture constructed with a ResNet34 encoder that was pre-trained on ImageNet<sup>46-</sup> <sup>49</sup>. The Adam optimizer was used<sup>50</sup>. The models were trained with a cyclic learning rate training policy<sup>51</sup>. 80% of the samples were used to train the model, and 20% were used for validation. Held-out test sets with images that were not used for training or validation were used to assess the final quality of all models. Four separate models were trained: one for each of the three long axis views, and one for the short axis view. During training, random perturbations of the input images (augmentations) were applied, including affine rotation, zooming, and modification of the brightness and contrast. For the short axis images, all images were resized initially to 104x104 pixels during the first half of training, and then to 224x224 pixels during the second half of training. The model was trained with a mini-batch size of 16 (with small images) or 8 (with large images). Maximum weight decay was 1E-03. The maximum learning rate was 1E-03, chosen based on the learning rate finder<sup>28,52</sup>. A focal loss function was used (with alpha 0.7 and gamma 0.7), which can improve performance in the case of imbalanced labels<sup>53</sup>. When training with small images, 60% of iterations were permitted to have an increasing learning rate during each epoch, and training was performed over 30 epochs while keeping the weights for all but the final layer frozen. Then, all layers were unfrozen, the learning rate was decreased to 1E-07, and the model was trained for an additional 10 epochs. When training with large images, 30% of

1 2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

- 1 iterations were permitted to have an increasing learning rate, and training was done for 30 epochs while
- 2 keeping all but the final layer frozen. Finally, all layers were unfrozen, the learning rate was decreased to
- 3 1E-07, and the model was trained for an additional 10 epochs. The semantic segmentation model training
- 4 hyperparameters for the two-, three-, and four-chamber long axis images were similar, and are detailed in
- 5 the Supplementary Note.

6

9

10

23

24

25

7 Each model was applied to all available images from its respective view that were available in the UK

To integrate the output from each of the four models into one LA volume estimate, Poisson surface

8 Biobank as of November 2020.

#### **Poisson surface reconstruction**

11 reconstruction was performed. Among the views included in the UK biobank cardiac MRI dataset, none 12 fully captures the 3-D anatomical structure of the LA. The short axis stack only occasionally included the 13 lower portion of the chamber, while the three long-axis (i.e., two-, three-, and four-chamber) views 14 provided only single-slice cross-sections of the LA at different orientations. To integrate information from 15 the four incomplete MRI views into a consistent 3D representation of the LA anatomy, we followed a procedure similar to Pirruccello et al. (2021)<sup>54</sup>. Briefly, we first co-rotated the MRI views into the same 16 17 reference system using standard DICOM metadata (i.e., from the Image Position (Patient) [0020,0032] 18 and Image Orientation (Patient) [0020,0037] tags). Then, we applied the Poisson surface reconstruction algorithm<sup>55</sup> to interpolate 3-D surfaces through the points marking the boundaries of the LA chamber 19 20 segmentations. In addition to the interpolation point coordinates, the Poisson algorithm requires as input 21 the local normal directions, which constrain the curvature of the reconstructed surface. In our approach, 22 we assumed that the normals lie onto the MRI view planes and are radially oriented outwards from the

center of gravity of the LA segmentation. 3D surfaces of the LA were reconstructed for each of the 50

MRI frames captured during the cardiac cycle. At each timepoint, the volume of the LA was computed

using routines for triangulated meshes included in the VTK library (Kitware Inc.). From the reconstructed

volume traces, we estimated the maximum and minimum LA volumes, as well as LA stroke volume and 1 2 emptying fraction. **Identification of abnormal atrial contraction patterns** 3 4 We sought to identify participants with abnormal atrial contraction patterns at the time of acquisition of 5 the magnetic resonance images. Although the imaging protocol was ECG-gated, the instantaneous ECG 6 signal was not available. Therefore, we used the filling patterns of the atrium and ventricle as markers of 7 normal filling. 8 9 To create a training set, we first pulled CINE videos from the 2-, 3-, and 4-chamber long axis views of all 10 participants with a history of AF. A cardiologist (JPP) evaluated whether the videos appeared to represent 11 a typical cardiac cycle including an atrial contraction. A deep learning model was then trained to classify 12 filling patterns as representing a normal atrial contraction or not. Each input channel represented the pixel 13 counts of a cardiac chamber from a different long-axis view, divided by the maximum number of pixels 14 seen for each channel for that participant, over the entire cardiac cycle. This approach prevented the 15 model from accessing information about the absolute size of the chambers, forcing it instead to identify 16 patterns based on relative size differences throughout the cardiac cycle. In total, 8 channels were used as 17 input: four from the 4-chamber long axis images (left atrium, right atrium, left ventricle, right ventricle), 18 two from the 3-chamber long axis images (left atrium, left ventricle), and two from the 2-chamber long 19 axis images (left atrium, left ventricle). Cases were excluded if all 8 channels were not available. 20 Therefore, the shape of the input was 50x8. Training was performed with FastAI version 2.2.5<sup>28</sup>, using the Timeseries AI library version 0.2.15 (github.com/timeseries AI/tsai) to train an Inception Time model<sup>56</sup>. 21 22 The Ranger optimization function was used with cross entropy loss, and the number of filters in the 23 InceptionTime model was 32, all of which are the software defaults in the TimeseriesAI library. Ranger 24 incorporates RAdam and Lookahead to improve training stability early and later during training, respectively<sup>57,58</sup>. 20% of samples were randomly chosen as the validation set. The model was trained with 25

1 a batch size of 32. Variable learning rates from 5E-06 to 5E-03 were permitted during training. Training was conducted using the One-Cycle policy for 20 epochs<sup>51,52</sup>. 2 Evaluation of the relationship between the left atrium and cardiovascular 3 diseases 4 5 We focused on three disease definitions related to LA structure and function: AF or flutter, ischemic 6 stroke, and heart failure (defined below in **Online Methods**). For prevalent disease that was diagnosed 7 prior to the time of imaging, linear models were used to test for an association between each disease (as a 8 binary independent variable) and LA phenotypes (as the dependent variables), adjusting for the MRI 9 serial number, sex, age, and the interaction between sex and age. 10 11 For incident disease, participants with pre-existing diagnoses prior to the MRI were excluded from the 12 analysis. A Cox proportional hazards model was used, with survival defined as the time between MRI and 13 either the time of censoring, or disease diagnosis. The model was adjusted for the MRI serial number, sex, 14 age, the interaction between sex and age, the cubic natural spline of height, the cubic natural spline of 15 weight, and the cubic natural spline of BMI. As a sensitivity analysis, adjustment was additionally made 16 for heart rate, P duration, QRS duration, P-Q interval, QTc interval, left ventricular end systolic volume, 17 left ventricular end diastolic volume, and left ventricular ejection fraction. 18 Genotyping, imputation, and genetic quality control 19 UK Biobank samples were genotyped on either the UK BiLEVE or UK Biobank Axiom arrays and 20 imputed into the Haplotype Reference Consortium panel and the UK10K+1000 Genomes panel<sup>59</sup>. Variant 21 positions were keyed to the GRCh37 human genome reference. Genotyped variants with genotyping call 22 rate < 0.95 and imputed variants with INFO score < 0.3 or minor allele frequency <= 0.005 in the 23 analyzed samples were excluded. After variant-level quality control, 11,253,549 imputed variants 24 remained for analysis. 25

1 Participants without imputed genetic data, or with a genotyping call rate < 0.98, mismatch between self-2 reported sex and sex chromosome count, sex chromosome aneuploidy, excessive third-degree relatives, or 3 outliers for heterozygosity were excluded from genetic analysis<sup>59</sup>. Participants were also excluded from 4 genetic analysis if they had a history of AF or flutter, hypertrophic cardiomyopathy, dilated 5 cardiomyopathy, heart failure, myocardial infarction, or coronary artery disease documented prior to the 6 time they underwent cardiovascular magnetic resonance imaging at a UK Biobank assessment center. Our 7 definitions of these diseases in the UK Biobank are provided in **Supplementary Table 12**. 8 Genome-wide association study of the left atrium 9 We analyzed four primary LA phenotypes, as well as LAmax, LAmin, and LASV estimates that were 10 adjusted for BSA or LVEDV. In total, we conducted 10 genome-wide association studies with these 11 traits. Before conducting genetic analyses, a rank-based inverse normal transformation was applied<sup>60</sup>. All traits were adjusted for sex, age at enrollment, age and age<sup>2</sup> at the time of MRI, the first 10 principal 12 13 components of ancestry, the genotyping array, and the MRI scanner's unique identifier. 14 15 BOLT-REML v2.3.4 was used to assess the SNP-heritability of the phenotypes, as well as their genetic correlation with one another using the directly genotyped variants in the UK Biobank<sup>61</sup>. Genome-wide 16 17 association studies for each phenotype were conducted using BOLT-LMM version 2.3.4 to account for cryptic population structure and sample relatedness<sup>61,62</sup>. We used the full autosomal panel of 714,577 18 19 directly genotyped SNPs that passed quality control to construct the genetic relationship matrix (GRM), 20 with covariate adjustment as noted above. Associations on the X chromosome were also analyzed, using 21 all autosomal SNPs and X chromosomal SNPs to construct the GRM (N=732,214 SNPs), with the same 22 covariate adjustments and significance threshold as in the autosomal analysis. In this analysis mode, 23 BOLT treats individuals with one X chromosome as having an allelic dosage of 0/2 and those with two X chromosomes as having an allelic dosage of 0/1/2. Variants with association P <  $5 \cdot 10^{-8}$ , a commonly used 24 25 threshold, were considered to be genome-wide significant.

1

2

3

4

5

6

7

9

11

14

17

20

21

22

We identified lead SNPs for each trait. Linkage disequilibrium (LD) clumping was performed with PLINK-1.9<sup>63</sup> using the same participants used for the GWAS. We outlined a 5-megabase window (-clump-kb 5000) and used a stringent LD threshold (--r2 0.001) in order to account for long LD blocks. With the independently significant clumped SNPs, distinct genomic loci were then defined by starting with the SNP with the strongest P value, excluding other SNPs within 500kb, and iterating until no SNPs remained. Independently significant SNPs that defined each genomic locus are termed the lead SNPs. 8 No lead SNPs deviated from Hardy-Weinberg equilibrium (HWE) at a threshold of  $P < 1E-06^{63}$ . 10 Linkage disequilibrium (LD) score regression analysis was performed using *ldsc* version 1.0.0<sup>29</sup>. With 12 ldsc, the genomic control factor (lambda GC) was partitioned into components reflecting polygenicity and 13 inflation, using the software's defaults. Genetic correlation with atrial fibrillation 15 We used *ldsc* version 1.0.1 to perform cross-trait LD score regression to estimate genetic correlation 16 between the LA measurements, atrial fibrillation (from Roselli, et al, 2018), and all-cause or cardioembolic stroke (from Malik, et al, 2018)<sup>31–33</sup>. Summary stats were pre-processed with the 18 munge\_sumstats.py script from ldsc 1.0.1 using the default settings, filtering out variants with imputation 19 INFO scores less than 0.9 or minor allele frequencies below 0.01, as well as strand-ambiguous variants. Overlap of left atrial loci with atrial fibrillation loci We identified the gene nearest to SNPs associated with AF from Supplementary Table 16 of Roselli, et  $al^{32}$ . For this exercise, we used each of the 134 SNPs that achieved association P < 5E-8 in the primary 23 GWAS (column 'I') or in the meta-analysis (column 'AD'). We counted the number of AF nearest genes 24 that fell within 500kb of the LA lead SNPs from our study. We used SNPsnap to generate 10,000 sets of 25 SNPs that matched the LA lead SNPs based on parameters including minor allele frequency, SNPs in LA Genetics - Page 19 of 44

linkage disequilibrium, distance from the nearest gene, and gene density<sup>34</sup>. We then repeated the same counting procedure for each of the 10,000 synthetic SNPsnap lead SNP lists, to set a neutral expectation for the number of overlapping AF nearest genes based on chance. This allowed us to compute a one-tailed permutation P value (with the most extreme possible P value based on 10,000 randomly chosen sets of SNPs being 1E-04). **Mendelian randomization** We sought to assess a potential causal relationship between LAmin and AF using Mendelian randomization (MR). We considered LAmin as the exposure and AF as the outcome. The genetic instruments for LAmin were generated using the genome-wide association results from this analysis. The variants from the exposure summary statistics were clumped with P < 1E-06,  $r^2 < 0.001$ , and a radius of 5 megabases using the *TwoSampleMR* package in R<sup>64</sup>. The variants with ambiguous alleles were removed. 19 variants were harmonized with a large AF GWAS that did not include UK Biobank participants<sup>35</sup>. The 13 inverse variance weighted (IVW) method was performed as the primary MR analysis. We also performed 14 simple median, weighted median, MR-Egger, and MR-PRESSO to account for violations of the instrumental variable assumptions. Since MR-Egger provides robust estimates under the InSIDE 16 (Instrument Strength Independent of Direct Effect) assumption, we additionally conducted the MR-Egger bootstrap method to confirm the results from MR-Egger. 18 To assess risk of pleiotropy of the LA genetic instruments, each SNP was tested for association with risk factors from CHARGE-AF<sup>4</sup> within the same participants in which the GWAS was conducted. Association between each of the 19 variants and seven risk factors (height, weight, systolic blood pressure, diastolic blood pressure, use of antihypertensive medications [ascertainment described below in **Online Methods**], diagnosis of diabetes, and current smoking) was tested in a linear regression model that accounted for age and age<sup>2</sup> at the time of MRI, sex, the MRI serial number, the genotyping array, and genetic principal

1

2

3

4

5

6 7

8

9

10

11

12

15

17

19

20

21

22

23

components 1-10. Associations were considered significant if they exceeded Bonferroni significance (P < 3.8E-04). To understand the bidirectional causal effects, we also performed an MR analysis using AF variants from the 2017 GWAS as the exposure and LAmin as the outcome. After applying the same clumping threshold and filtering methods to AF summary statistics, 36 remaining variants were harmonized with the LAmin association results and used to construct the instrumental variable. The primary and sensitivity analyses were then conducted in the same manner as described above. Polygenic risk analysis A polygenic score for the LAmin GWAS was computed using PRScs with a UK Biobank European ancestry linkage disequilibrium panel<sup>36</sup>. This method applies a continuous shrinkage prior to the SNP weights. PRScs was run in 'auto' mode on a per-chromosome basis. This mode places a standard half-Cauchy prior on the global shrinkage parameter and learns the global scaling parameter from the data; as a consequence, PRScs-auto does not require a validation data set for tuning. Based on the software default settings, only the 1.1 million SNPs found at HapMap3 sites that were also present in the UK Biobank were permitted to contribute to the score. This score was applied to the entire UK Biobank. Participants related within 3 degrees of kinship to those who had undergone MRI, based on the precomputed relatedness matrix from the UK Biobank, were excluded from analysis<sup>59</sup>. We analyzed the relationship between this polygenic prediction of the LAmin and incident diagnoses of AF in the UK Biobank using a Cox proportional hazards model as implemented by the R survival package<sup>65</sup>. We excluded participants with disease that was diagnosed prior to enrollment in the UK Biobank. We counted survival as the number of years between enrollment and disease diagnosis (for those with disease) or until death, loss to follow-up, or end of follow-up time (for those without disease). We adjusted for covariates including sex, the cubic basis spline of age at enrollment, the

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- 1 interaction between the cubic basis spline of age at enrollment and sex, the genotyping array, the first five
- 2 principal components of ancestry, and the cubic basis splines of height (cm), weight (kg), BMI (kg/m2),
- diastolic blood pressure (mmHg), and systolic blood pressure (mmHg).

#### **Definitions of diseases and medications**

- 5 We defined AF or flutter, dilated cardiomyopathy, hypertrophic cardiomyopathy, heart failure, diabetes,
- and ischemic stroke based on self report, ICD codes, and procedural codes (**Supplementary Table 12**).
- 7 The data were obtained from the UK Biobank in June 2020, at which time the recommended phenotype
- 8 censoring date was March 31, 2020. The UK Biobank defines that date as the last day of the month for
- 9 which the number of records is greater than 90% of the mean of the number of records for the previous
- three months (https://biobank.ndph.ox.ac.uk/ukb/exinfo.cgi?src=Data\_providers\_and\_dates).
- We identified participants taking antihypertensive medications based on the Anatomical Therapeutic
- 13 Classification (ATC)<sup>66</sup>. Medications taken by UK Biobank participants were previously mapped to ATC
- 14 codes<sup>67</sup>. We considered medications with ATC codes beginning with C02, C09, C08CA, C03AA,
- 15 C08CA01, or C03BA04 to be antihypertensives (medication names enumerated in **Supplementary Table**
- 16 13).

20

4

11

## 17 Acknowledgments

- 18 We would like to thank Mary O'Reilly from the Broad Institute PATTERN Team for contributing to the
- 19 graphical overview in Figure 1.

## References

- 2 1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang
- 3 TSM. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and
- 4 implications on the projections for future prevalence. Circulation 2006;114:119–125.
- 5 2. Marini Carmine, De Santis Federica, Sacco Simona, Russo Tommasina, Olivieri Luigi, Totaro
- 6 Rocco, Carolei Antonio. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke.
- 7 Stroke American Heart Association; 2005;36:1115–1119.
- 8 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the
- 9 Framingham Study. Stroke 1991;22:983–988.
- 10 4. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia
- 11 N, Fontes JD, Janssens ACJW, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA,
- 12 Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman A,
- 13 Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BHC, et al. Simple risk
- model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the
- 15 CHARGE-AF consortium. J Am Heart Assoc 2013;2:e000102.
- 16 5. Hulme OL, Khurshid S, Weng L-C, Anderson CD, Wang EY, Ashburner JM, Ko D, McManus
- 17 DD, Benjamin EJ, Ellinor PT, Trinquart L, Lubitz SA. Development and Validation of a Prediction
- 18 Model for Atrial Fibrillation Using Electronic Health Records. JACC Clin Electrophysiol 2019;5:1331–
- 19 1341.
- 20 6. Li Y-G, Pastori D, Farcomeni A, Yang P-S, Jang E, Joung B, Wang Y-T, Guo Y-T, Lip GYH. A
- 21 Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects:
- Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199
- 23 Korean Subjects. Chest 2019;155:510–518.
- 24 7. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of Blood Pressure on Left
- 25 Atrial Size. Hypertension American Heart Association; 1995;25:1155–1160.

- 1 8. Cioffi G, Gerdts E, Cramariuc D, Tarantini L, Di Lenarda A, Pulignano G, Sindaco DD,
- 2 Stefenelli C, Simone G de. Left atrial size and force in patients with systolic chronic heart failure:
- 3 Comparison with healthy controls and different cardiac diseases. Exp Clin Cardiol 2010;15:e45–e51.
- 4 9. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE. Atrial
- 5 enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation
- 6 1990:82:792–797.
- 7 10. Sardana Mayank, Lessard Darleen, Tsao Connie W., Parikh Nisha I., Barton Bruce A., Nah
- 8 Gregory, Thomas Randell C., Cheng Susan, Schiller Nelson B., Aragam Jayashri R., Mitchell Gary F.,
- 9 Vaze Aditya, Benjamin Emelia J., Vasan Ramachandran S., McManus David D. Association of Left
- 10 Atrial Function Index with Atrial Fibrillation and Cardiovascular Disease: The Framingham Offspring
- 11 Study. Journal of the American Heart Association American Heart Association; 7:e008435.
- 12 11. Vegte YJ van de, Siland JE, Rienstra M, Harst P van der. Atrial fibrillation and left atrial size and
- function: a Mendelian randomization study. Scientific Reports Nature Publishing Group; 2021;11:8431.
- 14 12. Henry W L, Morganroth J, Pearlman A S, Clark C E, Redwood D R, Itscoitz S B, Epstein S E.
- 15 Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation
- 16 American Heart Association; 1976;53:273–279.
- 17 13. Jin X, Pan J, Wu H, Xu D. Are left ventricular ejection fraction and left atrial diameter related to
- 18 atrial fibrillation recurrence after catheter ablation?: A meta-analysis. Medicine (Baltimore)
- 19 2018;97:e10822.
- 20 14. Lim DJ, Ambale-Ventakesh B, Ostovaneh MR, Zghaib T, Ashikaga H, Wu C, Watson KE,
- 21 Hughes T, Shea S, Heckbert SR, Bluemke DA, Post WS, Lima JAC. Change in left atrial function
- 22 predicts incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J Cardiovasc
- 23 Imaging 2019;20:979–987.
- 24 15. Park JJ, Park J-H, Hwang I-C, Park J-B, Cho G-Y, Marwick TH. Left Atrial Strain as a Predictor
- of New-Onset Atrial Fibrillation in Patients With Heart Failure. JACC Cardiovasc Imaging
- 26 2020;13:2071–2081.

- 1 16. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM,
- 2 Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume: important risk marker of
- 3 incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001;76:467–475.
- 4 17. Vaziri S M, Larson M G, Benjamin E J, Levy D. Echocardiographic predictors of nonrheumatic
- 5 atrial fibrillation. The Framingham Heart Study. Circulation American Heart Association; 1994;89:724–
- 6 730.
- 7 18. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of
- 8 stroke and death. The Framingham Heart Study. Circulation 1995;92:835–841.
- 9 19. Bouzas-Mosquera A, Broullón FJ, Álvarez-García N, Méndez E, Peteiro J, Gándara-Sambade T,
- 10 Prada O, Mosquera VX, Castro-Beiras A. Left atrial size and risk for all-cause mortality and ischemic
- 11 stroke. CMAJ 2011;183:E657-664.
- 12 20. Xu Y, Zhao L, Zhang L, Han Y, Wang P, Yu S. Left Atrial Enlargement and the Risk of Stroke:
- 13 A Meta-Analysis of Prospective Cohort Studies. Front Neurol 2020;11.
- 14 21. Fatkin D, Huttner IG, Johnson R. Genetics of atrial cardiomyopathy. Current Opinion in
- 15 Cardiology 2019;34:275–281.
- 16 22. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D'Avila
- 17 A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim Y-
- 18 H, Lip GYH, Ma C-S, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Wagoner DRV, Nattel S.
- 19 EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition,
- characterization, and clinical implication. Heart Rhythm Elsevier; 2017;14:e3–e40.
- 21 23. Wild PS, Felix JF, Schillert A, Teumer A, Chen M-H, Leening MJG, Völker U, Großmann V,
- 22 Brody JA, Irvin MR, Shah SJ, Pramana S, Lieb W, Schmidt R, Stanton AV, Malzahn D, Smith AV,
- 23 Sundström J, Minelli C, Ruggiero D, Lyytikäinen L-P, Tiller D, Smith JG, Monnereau C, Di Tullio MR,
- 24 Musani SK, Morrison AC, Pers TH, Morley M, Kleber ME, et al. Large-scale genome-wide analysis
- 25 identifies genetic variants associated with cardiac structure and function. J Clin Invest 2017;127:1798–
- **26** 1812.

- 1 24. Bai W, Suzuki H, Huang J, Francis C, Wang S, Tarroni G, Guitton F, Aung N, Fung K, Petersen
- 2 SE, Piechnik SK, Neubauer S, Evangelou E, Dehghan A, O'Regan DP, Wilkins MR, Guo Y, Matthews
- 3 PM, Rueckert D. A population-based phenome-wide association study of cardiac and aortic structure and
- 4 function. Nature Medicine Nature Publishing Group; 2020;1–9.
- 5 25. Thanaj M, Mielke J, McGurk KA, Bai W, Savioli N, Marvao A de, Meyer HV, Zeng L, Sohler F,
- 6 Wilkins MR, Ware JS, Bender C, Rueckert D, MacNamara A, Freitag DF, O'Regan DP. Genetic and
- 7 environmental determinants of diastolic heart function. medRxiv Cold Spring Harbor Laboratory Press;
- 8 2021;2021.06.07.21257302.
- 9 26. Petersen SE, Matthews PM, Bamberg F, Bluemke DA, Francis JM, Friedrich MG, Leeson P,
- 10 Nagel E, Plein S, Rademakers FE, Young AA, Garratt S, Peakman T, Sellors J, Collins R, Neubauer S.
- 11 Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank
- 12 rationale, challenges and approaches. Journal of Cardiovascular Magnetic Resonance BioMed Central;
- 13 2013;15:46.
- 14 27. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, Young AA,
- 15 Hudson S, Weale P, Garratt S, Collins R, Piechnik S, Neubauer S. UK Biobank's cardiovascular magnetic
- resonance protocol. J Cardiovasc Magn Reson 2016;18.
- 17 28. Howard J, Gugger S. Fastai: A Layered API for Deep Learning. Information Multidisciplinary
- Digital Publishing Institute; 2020;11:108.
- 19 29. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL,
- Neale BM, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide
- association studies. Nature Genetics 2015;47:291–295.
- 22 30. Aschard H, Vilhjálmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for Heritable Covariates
- 23 Can Bias Effect Estimates in Genome-Wide Association Studies. Am J Hum Genet 2015;96:329–339.
- 24 31. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, Duncan L, Perry JRB,
- 25 Patterson N, Robinson EB, Daly MJ, Price AL, Neale BM, Daly MJ, Price AL, Neale BM. An atlas of

- 1 genetic correlations across human diseases and traits. Nature Genetics Nature Publishing Group;
- 2 2015;47:1236–1241.
- 3 32. Roselli C, Chaffin MD, Weng L-C, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso
- 4 A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC,
- 5 Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H, Campbell A, Cappola TP, Carlquist J,
- 6 Chasman DI, Chen LY, Chen Y-DI, Choi E-K, Choi SH, Christophersen IE, et al. Multi-Ethnic Genome-
- 7 wide Association Study for Atrial Fibrillation. Nat Genet 2018;50:1225–1233.
- 8 33. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese
- 9 A-K, Laan SW van der, Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P,
- Amouyel P, Ay H, Bartz TM, Benavente OR, Bevan S, Boncoraglio GB, Brown RD, Butterworth AS,
- 11 Carrera C, Carty CL, Chasman DI, Chen W-M, Cole JW, Correa A, Cotlarciuc I, et al. Multiancestry
- 12 genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke
- 13 subtypes. Nat Genet 2018;50:524–537.
- 14 34. Pers TH, Timshel P, Hirschhorn JN. SNPsnap: a Web-based tool for identification and annotation
- of matched SNPs. Bioinformatics 2015;31:418–420.
- 16 35. Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, Lin H, Arking DE,
- 17 Smith AV, Albert CM, Chaffin M, Tucker NR, Li M, Klarin D, Bihlmeyer NA, Low S-K, Weeke PE,
- 18 Müller-Nurasyid M, Smith JG, Brody JA, Niemeijer MN, Dörr M, Trompet S, Huffman J, Gustafsson S,
- 19 Schurmann C, Kleber ME, Lyytikäinen L-P, Seppälä I, Malik R, et al. Large-scale analyses of common
- and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet 2017;49:946–952.
- 21 36. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression
- 22 and continuous shrinkage priors. Nature Communications Nature Publishing Group; 2019;10:1776.
- 23 37. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F,
- 24 Young N, Foster B, Moser M, Karasik E, Gillard B, Ramsey K, Sullivan S, Bridge J, Magazine H, Syron
- J, Fleming J, Siminoff L, Traino H, Mosavel M, Barker L, Jewell S, Rohrer D, Maxim D, Filkins D,

- 1 Harbach P, Cortadillo E, et al. The Genotype-Tissue Expression (GTEx) project. Nature Genetics
- 2 2013;45:580–585.
- 3 38. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific
- 4 haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics
- 5 2015;31:3555–3557.
- 6 39. Prins BP, Mead TJ, Brody JA, Sveinbjornsson G, Ntalla I, Bihlmeyer NA, Berg M van den,
- 7 Bork-Jensen J, Cappellani S, Van Duijvenboden S, Klena NT, Gabriel GC, Liu X, Gulec C, Grarup N,
- 8 Haessler J, Hall LM, Iorio A, Isaacs A, Li-Gao R, Lin H, Liu C-T, Lyytikäinen L-P, Marten J, Mei H,
- 9 Müller-Nurasyid M, Orini M, Padmanabhan S, Radmanesh F, Ramirez J, et al. Exome-chip meta-analysis
- identifies novel loci associated with cardiac conduction, including ADAMTS6. Genome Biol 2018;19:87.
- 11 40. Sotoodehnia N, Isaacs A, Bakker PIW de, Dörr M, Newton-Cheh C, Nolte IM, Harst P van der,
- Müller M, Eijgelsheim M, Alonso A, Hicks AA, Padmanabhan S, Hayward C, Smith AV, Polasek O,
- Giovannone S, Fu J, Magnani JW, Marciante KD, Pfeufer A, Gharib SA, Teumer A, Li M, Bis JC,
- 14 Rivadeneira F, Aspelund T, Köttgen A, Johnson T, Rice K, Sie MPS, et al. Common variants in 22 loci
- are associated with QRS duration and cardiac ventricular conduction. Nat Genet 2010;42:1068–1076.
- 16 41. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A,
- 17 Lorber A, Goldman B, Lancet D, Eldar M. A Missense Mutation in a Highly Conserved Region of
- 18 CASQ2 Is Associated with Autosomal Recessive Catecholamine-Induced Polymorphic Ventricular
- 19 Tachycardia in Bedouin Families from Israel. The American Journal of Human Genetics 2001;69:1378–
- 20 1384.
- 21 42. Ng Kevin, Titus Erron W., Lieve Krystien V., Roston Thomas M., Mazzanti Andrea, Deiter
- 22 Frederick H., Denjoy Isabelle, Ingles Jodie, Till Jan, Robyns Tomas, Connors Sean P., Steinberg
- 23 Christian, Abrams Dominic J., Pang Benjamin, Scheinman Melvin M., Bos J. Martijn, Duffett Stephen
- A., van der Werf Christian, Maltret Alice, Green Martin S., Rutberg Julie, Balaji Seshadri, Cadrin-
- Tourigny Julia, Orland Kate M., Knight Linda M., Brateng Caitlin, Wu Jeremy, Tang Anthony S., Skanes
- Allan C., Manlucu Jaimie, et al. An International Multicenter Evaluation of Inheritance Patterns,

- 1 Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular
- 2 Tachycardia. Circulation American Heart Association; 2020;142:932–947.
- 3 43. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J,
- 4 Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R.
- 5 UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of
- 6 middle and old age. PLoS medicine Public Library of Science; 2015;12:e1001779.
- 7 44. Pirruccello JP, Chaffin MD, Fleming SJ, Arduini A, Lin H, Khurshid S, Chou EL, Friedman SN,
- 8 Bick AG, Weng L-C, Choi SH, Akkad A-D, Batra P, Tucker NR, Hall AW, Roselli C, Benjamin EJ,
- 9 Vellarikkal SK, Gupta RM, Stegman CM, Ho JE, Hoffmann U, Lubitz SA, Philippakis A, Lindsay ME,
- 10 Ellinor PT. Deep learning enables genetic analysis of the human thoracic aorta. bioRxiv Cold Spring
- 11 Harbor Laboratory; 2020;2020.05.12.091934.
- 12 45. Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, Killeen T, Lin Z, Gimelshein N,
- Antiga L, Desmaison A, Köpf A, Yang E, DeVito Z, Raison M, Tejani A, Chilamkurthy S, Steiner B,
- 14 Fang L, Bai J, Chintala S. PyTorch: An Imperative Style, High-Performance Deep Learning Library.
- 15 arXiv:191201703 [cs, stat] 2019;
- 16 46. Deng J, Dong W, Socher R, Li L-J, Kai Li, Li Fei-Fei. ImageNet: A large-scale hierarchical
- 17 image database. 2009 IEEE Conference on Computer Vision and Pattern Recognition 2009, p. 248–255.
- 18 47. He K, Zhang X, Ren S, Sun J. Deep Residual Learning for Image Recognition. arXiv:151203385
- 19 [cs] 2015;
- 48. Krizhevsky A, Sutskever I, Hinton GE. ImageNet Classification with Deep Convolutional Neural
- 21 Networks.
- 22 49. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image
- 23 Segmentation. arXiv:150504597 [cs] 2015;
- 24 50. Kingma DP, Ba J. Adam: A Method for Stochastic Optimization, arXiv:14126980 [cs] 2017;
- 25 51. Smith LN. Cyclical Learning Rates for Training Neural Networks. arXiv:150601186 [cs] 2015;

- 1 52. Smith LN. A disciplined approach to neural network hyper-parameters: Part 1 -- learning rate,
- batch size, momentum, and weight decay. arXiv:180309820 [cs, stat] 2018;
- 3 53. Lin T-Y, Goyal P, Girshick R, He K, Dollár P. Focal Loss for Dense Object Detection.
- 4 arXiv:170802002 [cs] 2018;
- 5 54. Pirruccello JP, Achille PD, Nauffal V, Nekoui M, Friedman SN, Klarqvist MDR, Chaffin MD,
- 6 Khurshid S, Roselli C, Batra P, Ng K, Lubitz SA, Ho JE, Lindsay ME, Philippakis AA, Ellinor PT.
- 7 Genetic Analysis of Right Heart Structure and Function in 40,000 People. bioRxiv Cold Spring Harbor
- 8 Laboratory; 2021;2021.02.05.429046.
- 9 55. Kazhdan M, Hoppe H. Screened poisson surface reconstruction. ACM Trans Graph
- 10 2013;32:29:1-29:13.
- 11 56. Fawaz HI, Lucas B, Forestier G, Pelletier C, Schmidt DF, Weber J, Webb GI, Idoumghar L,
- 12 Muller P-A, Petitjean F. InceptionTime: Finding AlexNet for Time Series Classification. Data Min
- 13 Knowl Disc 2020;34:1936–1962.
- 14 57. Liu L, Jiang H, He P, Chen W, Liu X, Gao J, Han J. On the Variance of the Adaptive Learning
- 15 Rate and Beyond. arXiv:190803265 [cs, stat] 2020;
- 16 58. Zhang MR, Lucas J, Hinton G, Ba J. Lookahead Optimizer: k steps forward, 1 step back.
- 17 arXiv:190708610 [cs, stat] 2019;
- 18 59. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
- 19 Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N,
- 20 Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. Nature
- 21 2018;562:203.
- 22 60. Yang J, Loos RJF, Powell JE, Medland SE, Speliotes EK, Chasman DI, Rose LM, Thorleifsson
- 23 G, Steinthorsdottir V, Mägi R, Waite L, Smith AV, Yerges-Armstrong LM, Monda KL, Hadley D,
- Mahajan A, Li G, Kapur K, Vitart V, Huffman JE, Wang SR, Palmer C, Esko T, Fischer K, Zhao JH,
- Demirkan A, Isaacs A, Feitosa MF, Luan J, Heard-Costa NL, et al. FTO genotype is associated with
- phenotypic variability of body mass index. Nature 2012;490:267–272.

- 1 61. Loh P-R, Tucker G, Bulik-Sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, Chasman
- 2 DI, Ridker PM, Neale BM, Berger B, Patterson N, Price AL. Efficient Bayesian mixed-model analysis
- 3 increases association power in large cohorts. Nature Genetics Nature Publishing Group; 2015;47:284–
- 4 290.
- 5 62. Loh P-R, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-scale
- datasets. Nature Genetics Nature Publishing Group; 2018;50:906–908.
- 7 63. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:
- 8 rising to the challenge of larger and richer datasets. Gigascience 2015;4.
- 9 64. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden
- 10 J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM,
- Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference
- across the human phenome. Loos R, ed. eLife eLife Sciences Publications, Ltd; 2018;7:e34408.
- 13 65. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York:
- 14 Springer-Verlag; 2000.
- 15 66. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B,
- 16 Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. Nat Rev Drug
- 17 Discov 2017;16:19–34.
- 18 67. Wu Y, Byrne EM, Zheng Z, Kemper KE, Yengo L, Mallett AJ, Yang J, Visscher PM, Wray NR.
- 19 Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat
- 20 Commun 2019;10.

# Appendices

1

## 2 Data availability

- 3 UK Biobank data are made available to researchers from research institutions with genuine research
- 4 inquiries, following IRB and UK Biobank approval. GWAS summary statistics and polygenic score
- 5 weights will be available upon publication at the Broad Institute Cardiovascular Disease Knowledge
- 6 Portal (http://www.broadcvdi.org). LA measurements will be returned to the UK Biobank for use by any
- 7 approved researcher. All other data are contained within the article and its supplementary information.

#### 8 Code availability

- 9 The code used to perform Poisson surface reconstruction from segmentation output is located at
- 10 https://github.com/broadinstitute/ml4h and is available under an open-source BSD license.

#### 11 Author contributions

- 12 PTE and JPP conceived of the study. JPP annotated images. JPP trained the deep learning models. PD
- 13 performed surface reconstruction. JPP, PD, SJ, and SHC conducted bioinformatic analyses. JPP, SHC,
- 14 and PTE wrote the paper. All other authors contributed to the analysis plan or provided critical revisions.

#### 15 Sources of funding

- 16 This work was supported by the Fondation Leducq (14CVD01), and by grants from the National
- 17 Institutes of Health to Dr. Ellinor (1RO1HL092577, K24HL105780) and Dr. Ho (R01HL134893,
- 18 R01HL140224, K24HL153669). This work was supported by a John S LaDue Memorial Fellowship and
- 19 the Sarnoff Cardiovascular Research Foundation Scholar Award to Dr. Pirruccello. Dr. Nauffal is
- supported by NIH grant 5T32HL007604-35. Dr. Khurshid is supported by NIH grant T32HL007208. Dr.
- Lubitz is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007.
- 22 This work was supported by a grant from the American Heart Association Strategically Focused Research
- Networks to Dr. Ellinor. Dr. Lindsay is supported by the Fredman Fellowship for Aortic Disease and the

- 1 Toomey Fund for Aortic Dissection Research. This work was funded by a collaboration between the
- 2 Broad Institute and IBM Research.
- 3 Disclosures
- 4 Dr. Pirruccello has served as a consultant for Maze Therapeutics. Dr. Lubitz receives sponsored research
- 5 support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has
- 6 consulted for Bristol Myers Squibb / Pfizer and Bayer AG, and participates in a research collaboration
- 7 with IBM. Dr. Ng is employed by IBM Research. Dr. Ho is supported by a grant from Bayer AG focused
- 8 on machine-learning and cardiovascular disease and a research grant from Gilead Sciences. Dr. Ho has
- 9 received research supplies from EcoNugenics. Dr. Philippakis is employed as a Venture Partner at GV; he
- 10 is also supported by a grant from Bayer AG to the Broad Institute focused on machine learning for
- 11 clinical trial design. Dr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on
- the genetics and therapeutics of cardiovascular diseases. Dr. Ellinor has also served on advisory boards or
- 13 consulted for Bayer AG, Quest Diagnostics, MyoKardia and Novartis. Remaining authors report no
- disclosures.

# 1 Tables

4

# 2 Table 1: Participant characteristics

	Women	Men	Both
N	18,916	16,133	35,049
Age at time of MRI	64 (8)	65 (8)	64 (8)
BMI (kg/m^2)	26 (5)	27 (4)	26 (4)
Height (cm)	163 (6)	176 (7)	169 (9)
Weight (kg)	69 (13)	83 (13)	75 (15)
Systolic Blood Pressure (mmHg)	136 (19)	142 (17)	139 (19)
Diastolic Blood Pressure (mmHg)	77 (10)	81 (10)	79 (10)
Left atrium maximum volume (cm^3)	64 (15)	79 (19)	71 (18)
Left atrium minimum volume (cm^3)	28 (9)	37 (12)	32 (11)
Left atrium stroke volume (cm^3)	36 (8)	43 (11)	39 (10)
Left atrium emptying fraction (%)	57 (8)	54 (7)	56 (8)

<sup>3</sup> Characteristics of the participants who contributed to the GWAS are listed as mean (standard deviation).

## Table 2: GWAS lead SNPs

Trait	CHR	ВР	dbSNP	Effect Allele	Other Allele	EAF	BETA	SE	P	Nearest Gene
LAmax	6	31294375	rs9265346	G	A	0.33	0.045	0.007	1.10E-09	HLA-B
LAmax	6	79554193	rs6926537	Т	A	0.512	-0.039	0.007	9.10E-09	IRAK1BP1
LAmax	6	107433645	rs60237682	Т	С	0.683	-0.041	0.007	3.80E-08	BEND3
LAmax	12	66343400	rs1038196	G	С	0.486	0.039	0.007	1.10E-08	HMGA2
LAmax	19	46213416	rs62111731	A	G	0.479	0.042	0.007	7.10E-10	FBXO46
LAmax indexed	2	179650954	rs6715901	G	A	0.507	-0.043	0.008	1.20E-08	TTN
LAmax indexed	4	111665783	rs2634073	Т	С	0.166	0.057	0.01	2.00E-08	PITX2
LAmax indexed	5	32831670	rs13154066	Т	С	0.402	-0.05	0.008	6.60E-11	NPR3
LAmax indexed	6	31229203	rs9264391	G	A	0.893	-0.089	0.014	9.30E-11	HLA-C
LAmax indexed	6	107442277	rs9480737	A	G	0.682	-0.05	0.008	8.80E-10	BEND3
LAmax indexed	19	46166806	rs140153691	Т	TGC	0.639	-0.047	0.008	4.10E-09	GIPR
LAmax indexed	22	26156505	rs133873	Т	A	0.775	-0.055	0.009	9.60E-10	MYO18B
LAEF	1	51322205	rs79948214	A	G	0.984	0.161	0.029	4.70E-08	FAF1
LAEF	1	116310967	rs4074536	Т	C	0.702	-0.052	0.008	7.80E-11	CASQ2
LAEF	14	23874117	rs440466	T	C	0.622	0.056	0.008	7.30E-14	MYH6
LAEF	22	26159289	rs133885	G	A	0.548	0.046	0.007	3.60E-10	MYO18B
LAmin	6	31294375	rs9265346	G	A	0.33	0.044	0.007	8.30E-09	HLA-B
LAmin	6	79518638	rs35790661	С	CCA	0.63	-0.043	0.007	4.40E-09	IRAK1BP1
LAmin	6	107442277	rs9480737	A	G	0.682	-0.041	0.007	3.10E-08	BEND3
LAmin	10	92681480	rs780162510	CATA	С	0.49	0.04	0.007	2.20E-08	ANKRD1
LAmin	11	65336819	rs3782089	С	Т	0.928	0.074	0.013	4.70E-08	SSSCA1
LAmin	15	99248018	rs4966014	C	Т	0.3	0.045	0.008	4.20E-09	IGF1R
LAmin	19	46315357		AT	A	0.476	0.047	0.007	1.20E-11	RSPH6A
LAmin	22	26164079	rs133902	С	Т	0.56	-0.041	0.007	4.30E-09	MYO18B
LAmin indexed	2	3912741	rs56289263	С	T	0.938	-0.093	0.017	4.40E-08	DCDC2C
LAmin indexed	2	179650954	rs6715901	G	A	0.507	-0.041	0.007	4.50E-08	TTN
LAmin indexed	4	24289655	rs1533093	С	Т	0.862	-0.062	0.011	3.80E-08	DHX15
LAmin indexed	4	111665783	rs2634073	Т	С	0.166	0.057	0.01	1.20E-08	PITX2
LAmin indexed	5	32831670	rs13154066	Т	С	0.402	-0.043	0.008	1.40E-08	NPR3
LAmin indexed	6	31294375	rs9265346	G	A	0.33	0.047	0.008	1.00E-08	HLA-B

LAmin indexed	6	107442277	rs9480737	A	G	0.682	-0.049	0.008	1.00E-09	BEND3
LAmin indexed	8	97223162	rs35216833	С	Т	0.456	0.042	0.007	1.00E-08	UQCRB
LAmin indexed	10	92586289	rs112343361	A	ACT	0.497	-0.046	0.008	1.80E-09	HTR7
LAmin indexed	15	99248018	rs4966014	С	Т	0.3	0.047	0.008	1.80E-08	IGF1R
LAmin indexed	17	45097337	rs8078336	G	Т	0.965	-0.137	0.025	2.70E-08	GOSR2
LAmin indexed	19	46292259	rs7246377	G	A	0.534	-0.049	0.007	2.80E-11	DMWD
LAmin indexed	22	26156512	rs133874	A	G	0.773	-0.061	0.009	6.80E-12	MYO18B
LASV	6	31225196	rs199610865	T	TA	0.853	-0.055	0.01	2.90E-08	HLA-C
LASV	14	23869029	rs376439	A	G	0.606	0.045	0.007	2.70E-10	MYH6
LASV indexed	6	31225196	rs199610865	Т	TA	0.853	-0.067	0.011	4.70E-10	HLA-C
LASV indexed	9	136138765	rs8176685	GCGCC CACCA CTA	G	0.82	-0.059	0.01	3.20E-09	OBP2B
LASV indexed	14	23869029	rs376439	A	G	0.606	0.048	0.008	8.10E-10	МҮН6

<sup>1</sup> **BP**: GRCh37-base position. **dbSNP**: dbSNP identifier, where available. **EAF**: Effect allele frequency.

<sup>2</sup> **BETA**: BOLT-LMM effect size of the effect allele. **SE**: Standard error. **P**: BOLT-LMM P-value.

<sup>3 &</sup>quot;Indexed" indicates that the trait has been divided by body surface area.

1


2

3

9

## Figure 1


four imaging planes.




4 Study overview. Left panel: Orientation of the different planes in which images of the atrium were 5 captured. Middle panel: Example images from each of the four imaging planes; after interpretation with 6 the deep learning model, the left atrium is colored in blue. **Right panel**: schematic overview representing 7 reconstruction of the left atrium based on information obtained from the deep learning output from the 8

LA Genetics - Page 37 of 44

1




- 3 In the **left panel**, a flow diagram breaks down the imaged population into groups with and without AF,
- 4 and then further into groups that do and do not appear to have normal atrial contraction patterns. In the
- 5 **right panel**, the LAmin volume is depicted for these groups with violin plots; the median for each group
- 6 is demarcated with a vertical line.




Left panel ("Prevalent disease"): the difference in LA volumes (Y axis) between UK Biobank participants with atrial fibrillation ("AF"), heart failure ("CHF"), hypertension ("HTN"), or stroke occurring prior to MRI compared to participants without disease (X axis). Right panel ("Incident disease"): hazard ratios for incidence of AF, CHF, HTN, and stroke (Y axis) occurring after MRI per 1 standard deviation increase in LA volumes (X axis). Point estimates are represented by a circle; 95% confidence intervals for the estimate are represented by error bars.

1




- 1 Manhattan plots show the chromosomal position (**X-axis**) and the strength of association (-log10 of the P
- 2 value, **Y-axis**) for all raw and BSA-indexed phenotypes. Loci that contain SNPs with P < 5E-08 are
- 3 colored red and labeled with the name of the nearest gene to the most strongly associated SNP.

1



- 3 The 8 loci associated with LA measurements and AF are displayed. All loci (except those near CASO2
- 4 and *PITX2*) have multiple patterns of linkage disequilibrium and are therefore represented multiple times.
- 5 Black dots represent an association P < 5E-8; gray dots represent P < 5E-6. Effect sizes are oriented with
- 6 respect to the minor allele. Effect size for AF loci represents the logarithm of the odds ratio.

1



- 3 Disease incidence curves for the 417,881 participants who were unrelated to within 3 degrees of the
- 4 participants who underwent MRI in the UK Biobank. Those in the top 5% for the BSA-indexed LAmin
- 5 PRS are depicted in red; the remaining 95% are in gray. **X-axis**: years since enrollment in the UK
- 6 Biobank. **Y-axis**: cumulative incidence of AF (19,875 cases in the bottom 95% and 1,272 cases in the top
- 7 5%). Those in the top 5% of genetically predicted LAmin-indexed had an increased risk of AF (Cox HR
- 8 1.22, P = 1.2E-11) compared with those in the remaining 95% in up to 12 years of follow-up time after
- 9 UK Biobank enrollment.